SK287218B6 - Použitie avidínu alebo streptavidínu na prípravu liečiv na neutralizáciu antitrombotickej aktivity syntetických polysacharidov - Google Patents

Použitie avidínu alebo streptavidínu na prípravu liečiv na neutralizáciu antitrombotickej aktivity syntetických polysacharidov Download PDF

Info

Publication number
SK287218B6
SK287218B6 SK5031-2009A SK50312009A SK287218B6 SK 287218 B6 SK287218 B6 SK 287218B6 SK 50312009 A SK50312009 A SK 50312009A SK 287218 B6 SK287218 B6 SK 287218B6
Authority
SK
Slovakia
Prior art keywords
methyl
glucopyranosyl
tri
compound
preparation
Prior art date
Application number
SK5031-2009A
Other languages
English (en)
Slovak (sk)
Inventor
Philippe Duchaussoy
Jean Marc Herbert
Maurice Petitou
Pierre Savi
Original Assignee
Sanofi - Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi - Aventis filed Critical Sanofi - Aventis
Publication of SK287218B6 publication Critical patent/SK287218B6/sk

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08BPOLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08BPOLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08BPOLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Polymers & Plastics (AREA)
  • Materials Engineering (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
SK5031-2009A 2000-09-22 2001-09-20 Použitie avidínu alebo streptavidínu na prípravu liečiv na neutralizáciu antitrombotickej aktivity syntetických polysacharidov SK287218B6 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0012094A FR2814463B1 (fr) 2000-09-22 2000-09-22 Nouveaux polysaccharides a activite antithrombotique comprenant au moins une liaison covalente avec la biotine ou un derive de la biotine
PCT/FR2001/002918 WO2002024754A1 (fr) 2000-09-22 2001-09-20 Polysaccharides a activite antithrombotique comprenant au moins une liaison covalente avec la biotine ou un derive de la biotine

Publications (1)

Publication Number Publication Date
SK287218B6 true SK287218B6 (sk) 2010-03-08

Family

ID=8854579

Family Applications (2)

Application Number Title Priority Date Filing Date
SK5031-2009A SK287218B6 (sk) 2000-09-22 2001-09-20 Použitie avidínu alebo streptavidínu na prípravu liečiv na neutralizáciu antitrombotickej aktivity syntetických polysacharidov
SK356-2003A SK287054B6 (sk) 2000-09-22 2001-09-20 Polysacharidy s antitrombotickou aktivitou obsahujúce aspoň jednu kovalentnú väzbu s biotínom alebo derivátom biotínu a ich použitie pri liečení

Family Applications After (1)

Application Number Title Priority Date Filing Date
SK356-2003A SK287054B6 (sk) 2000-09-22 2001-09-20 Polysacharidy s antitrombotickou aktivitou obsahujúce aspoň jednu kovalentnú väzbu s biotínom alebo derivátom biotínu a ich použitie pri liečení

Country Status (40)

Country Link
US (3) US6844329B2 (zh)
EP (1) EP1322673B1 (zh)
JP (2) JP5016778B2 (zh)
KR (2) KR20080049139A (zh)
CN (1) CN1235914C (zh)
AR (1) AR030774A1 (zh)
AT (1) ATE374215T1 (zh)
AU (2) AU2001291960C1 (zh)
BG (1) BG66191B1 (zh)
BR (1) BR0114007A (zh)
CA (1) CA2418815C (zh)
CY (1) CY1108076T1 (zh)
CZ (1) CZ300856B6 (zh)
DE (1) DE60130669T2 (zh)
DK (1) DK1322673T3 (zh)
EA (1) EA005133B1 (zh)
EC (1) ECSP034514A (zh)
EE (1) EE05202B1 (zh)
ES (1) ES2292625T3 (zh)
FR (1) FR2814463B1 (zh)
GE (1) GEP20053616B (zh)
HK (1) HK1053316A1 (zh)
HR (1) HRP20030219B1 (zh)
HU (2) HUP0303551A3 (zh)
IL (2) IL154848A0 (zh)
IS (1) IS2550B (zh)
ME (2) ME00080B (zh)
MX (1) MXPA03002483A (zh)
NO (2) NO332905B1 (zh)
NZ (1) NZ524472A (zh)
PE (1) PE20020471A1 (zh)
PL (1) PL206727B1 (zh)
PT (1) PT1322673E (zh)
RS (1) RS50730B (zh)
SI (1) SI1322673T1 (zh)
SK (2) SK287218B6 (zh)
TW (1) TWI308153B (zh)
UA (1) UA79736C2 (zh)
WO (1) WO2002024754A1 (zh)
ZA (1) ZA200301692B (zh)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2814463B1 (fr) * 2000-09-22 2002-11-15 Sanofi Synthelabo Nouveaux polysaccharides a activite antithrombotique comprenant au moins une liaison covalente avec la biotine ou un derive de la biotine
FR2874924B1 (fr) * 2004-09-09 2006-12-01 Sanofi Aventis Sa Hexadecasaccharides biotinyles, leur preparation et leur utilisation therapeutique
TWI403334B (zh) * 2004-12-23 2013-08-01 Merck Sharp & Dohme 包含生物素殘基之抗血栓雙重抑制劑
TWI376234B (en) * 2005-02-01 2012-11-11 Msd Oss Bv Conjugates of a polypeptide and an oligosaccharide
NZ567221A (en) * 2005-10-10 2010-06-25 Organon Nv Anticoagulant antithrombotic dual inhibitors comprising a biotin label
CN101312747B (zh) * 2005-10-10 2013-03-20 Msd欧斯股份有限公司 包括生物素标记的抗血栓形成双重抑制剂
CN1317035C (zh) * 2005-10-24 2007-05-23 天津大学 基于酰肼基的微粒表面多重生物功能因子组装方法
EP1886696A1 (en) * 2006-08-03 2008-02-13 Endotis Pharma Conjugates of antithrombin binding oligosaccharide derivatives and therapeutic proteins
FR2912409B1 (fr) * 2007-02-14 2012-08-24 Sanofi Aventis Heparines de bas poids moleculaire comprenant au moins une liaison covalente avec la biotine ou un derive de la biotine leur procede de preparation,leur utilisation
EP2233143A1 (en) 2009-03-24 2010-09-29 Sanofi-Aventis Use of idrabiotaparinux for decreasing the incidence of bleedings during an antithrombotic treatment
EP2145624A1 (en) 2008-07-18 2010-01-20 Sanofi-Aventis Use of idrabiotaparinux for decreasing the incidence of bleedings during an antithrombotic treatment
TW201006479A (en) * 2008-07-18 2010-02-16 Sanofi Aventis Use of idrabiotaparinux for decreasing the incidence of bleedings during an antithrombotic treatment
FR2935386B1 (fr) * 2008-08-26 2010-09-10 Sanofi Aventis Nouveaux polysaccharides a activite antithrombotique comprenant une liaion covalente avec une chaine amine
EP2323605A4 (en) * 2008-09-10 2014-02-05 Syneron Medical Ltd TRANSDERMAL RELEASE OF OLIGOSACCHARIDES
MX2019001413A (es) 2008-12-19 2019-08-12 Supernus Pharmaceuticals Inc Uso de molindona para el tratamiento de agresion.
FR2952935B1 (fr) 2009-11-20 2011-12-02 Sanofi Aventis Procede de preparation du n-biotinyl-6-aminocaproate de n succinimidyle
JP6109574B2 (ja) 2009-12-18 2017-04-05 カタラン、フランス、バインハイム、ソシエテ、アノニムCatalent France Beinheim Sa 合成オリゴサッカリドを含有する医薬経口剤形
CZ302669B6 (cs) * 2010-03-29 2011-08-24 Univerzita Palackého v Olomouci Efektivní zpusob biotinylace aminosloucenin pomocí syntézy na pevné fázi pro potreby afinitní chromatografie
CZ302510B6 (cs) * 2010-03-29 2011-06-22 Univerzita Palackého v Olomouci Efektivní zpusob biotinylace sloucenin s karboxylovou skupinou pomocí syntézy na pevné fázi pro potreby afinitní chromatografie
AU2011235222B2 (en) 2010-03-31 2014-09-25 Supernus Pharmaceuticals Inc. Stabilized formulations of CNS compounds
JP2013537181A (ja) * 2010-09-10 2013-09-30 サノフイ 抗血栓活性及び改善された代謝安定性を有するビオチン化多糖類
FR2964660B1 (fr) * 2010-09-10 2012-09-28 Sanofi Aventis Nouveaux polysaccharides biotinyles a activite antithrombotique et presentant une stabilite metabolique amelioree
EP2484366A1 (en) 2011-02-07 2012-08-08 Sanofi Idrabiotaparinux for the treatment of pulmonary embolism and for the secondary prevention of venous thromboembolic events
EP2721044B1 (en) * 2011-06-17 2015-11-18 Carbomimetics Synthetic pentasaccharides having short half-life and high activity
EP3524251A1 (en) * 2012-11-13 2019-08-14 Supernus Pharmaceuticals, Inc. Method of treatment of aggression
WO2015195404A1 (en) 2014-06-20 2015-12-23 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods for detection of an analyte by movement of tethered microparticles
WO2016205239A1 (en) 2015-06-15 2016-12-22 The United States Of America, As Represented By The Secretary Department Of Health And Human Services Non-hormonal mammalian sperm decoy contraception based on the n-terminus of the zp2 protein
EP3529205B1 (en) 2016-10-21 2022-06-15 The United States of America, as represented by the Secretary, Department of Health and Human Services Molecular nanotags
CN108976318B (zh) * 2017-06-01 2021-03-30 首都医科大学 单-6-(生物素酰胺基)-6-脱氧-β-环糊精及其制备方法和应用
WO2019133727A1 (en) 2017-12-29 2019-07-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Universal influenza virus probe set for enrichment of any influenza virus nucleic acid
WO2021007429A1 (en) 2019-07-09 2021-01-14 Optimvia Llc Methods for synthesizing anticoagulant polysaccharides
US20230047654A1 (en) * 2019-10-17 2023-02-16 Autonetworks Technologies, Ltd. Wiring module
WO2022056078A1 (en) 2020-09-11 2022-03-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Rnase h-assisted detection assay for rna (radar)
WO2024191684A1 (en) 2023-03-10 2024-09-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Detection of hepatitis c virus ribonucleic acid from whole blood using reverse transcription loop-mediated isothermal amplification

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3960884A (en) * 1974-04-24 1976-06-01 Sergei Ivanovich Zavyalov Method of preparing racemic biotin
AU563351C (en) * 1982-01-15 2003-06-19 Glaxo Group Limited Synthesis of oligosaccharides
IL102758A (en) * 1991-08-23 1997-03-18 Akzo Nv Glycosaminoglycanoid derivatives, their preparation and pharmaceutical compositions comprising them
US20010023288A1 (en) * 1999-07-07 2001-09-20 Wilbur D. Scott Trifunctional reagent for conjugation to a biomolecule
FR2751334B1 (fr) * 1996-07-19 1998-10-16 Sanofi Sa Polysaccharides synthetiques, procede pour leur preparation et compositions pharmaceutiques les contenant
FR2773801B1 (fr) * 1998-01-19 2000-05-12 Sanofi Sa Nouveaux pentasaccharides, procedes pour leurs preparations et compositions pharmaceutiques les contenant
FR2773804B1 (fr) * 1998-01-19 2000-02-18 Sanofi Sa Polysaccharides de synthese, procede pour leur preparation et compositions pharmaceutiques le contenant
GB2335490B (en) * 1998-03-20 2003-05-14 Ortho Clinical Diagnostics An assay surface that permits an analyte releasiing step
AU8366398A (en) * 1998-07-07 2000-01-24 Department Of Radiation Oncology University Of Washington Trifunctional reagent for conjugation to a biomolecule
KR20010030803A (ko) 1998-07-31 2001-04-16 야마야 와따루 신규 글리코사미노글리칸 및 이를 함유하는 의약 조성물
FR2814463B1 (fr) * 2000-09-22 2002-11-15 Sanofi Synthelabo Nouveaux polysaccharides a activite antithrombotique comprenant au moins une liaison covalente avec la biotine ou un derive de la biotine

Also Published As

Publication number Publication date
PE20020471A1 (es) 2002-06-01
HU1400034D0 (hu) 2004-03-01
DE60130669D1 (de) 2007-11-08
IL154848A0 (en) 2003-10-31
AU2001291960C1 (en) 2009-10-08
HRP20030219B1 (en) 2011-10-31
EP1322673B1 (fr) 2007-09-26
ECSP034514A (es) 2003-04-25
ES2292625T3 (es) 2008-03-16
NO20031295L (no) 2003-05-22
ZA200301692B (en) 2004-03-01
PL363368A1 (en) 2004-11-15
KR100891388B1 (ko) 2009-04-02
PL206727B1 (pl) 2010-09-30
CY1108076T1 (el) 2014-02-12
ME00080B (me) 2010-10-10
HUP0303551A3 (en) 2004-03-29
KR20080049139A (ko) 2008-06-03
GEP20053616B (en) 2005-09-26
CZ300856B6 (cs) 2009-08-26
DK1322673T3 (da) 2008-01-14
YU19703A (sh) 2006-05-25
CN1466594A (zh) 2004-01-07
JP2004509902A (ja) 2004-04-02
WO2002024754A1 (fr) 2002-03-28
AU9196001A (en) 2002-04-02
CA2418815C (en) 2011-05-10
IL154848A (en) 2010-11-30
AR030774A1 (es) 2003-09-03
AU2001291960B2 (en) 2007-03-01
IS6733A (is) 2003-02-28
US20040024197A1 (en) 2004-02-05
JP2012131809A (ja) 2012-07-12
BR0114007A (pt) 2003-08-12
CZ2003814A3 (cs) 2003-06-18
DE60130669T2 (de) 2008-07-17
MXPA03002483A (es) 2004-05-24
EE200300114A (et) 2005-02-15
NO20110401L (no) 2003-05-22
US20110144042A1 (en) 2011-06-16
US7943595B2 (en) 2011-05-17
US20060160768A1 (en) 2006-07-20
EE05202B1 (et) 2009-08-17
NO332905B1 (no) 2013-01-28
EP1322673A1 (fr) 2003-07-02
KR20030055269A (ko) 2003-07-02
EA005133B1 (ru) 2004-12-30
ATE374215T1 (de) 2007-10-15
NO20031295D0 (no) 2003-03-20
FR2814463A1 (fr) 2002-03-29
HUP0303551A2 (hu) 2004-03-01
WO2002024754A8 (fr) 2003-07-03
PT1322673E (pt) 2007-12-03
EA200300237A1 (ru) 2003-08-28
US8318696B2 (en) 2012-11-27
SI1322673T1 (sl) 2008-02-29
US6844329B2 (en) 2005-01-18
SK287054B6 (sk) 2009-10-07
FR2814463B1 (fr) 2002-11-15
UA79736C2 (uk) 2007-07-25
JP5016778B2 (ja) 2012-09-05
BG66191B1 (bg) 2011-12-30
HK1053316A1 (en) 2003-10-17
CN1235914C (zh) 2006-01-11
HRP20030219A2 (en) 2003-06-30
SK3562003A3 (en) 2003-11-04
TWI308153B (en) 2009-04-01
IS2550B (is) 2009-10-15
CA2418815A1 (en) 2002-03-28
MEP23608A (en) 2010-06-10
BG107650A (bg) 2003-11-28
RS50730B (sr) 2010-08-31
NZ524472A (en) 2004-10-29

Similar Documents

Publication Publication Date Title
SK287218B6 (sk) Použitie avidínu alebo streptavidínu na prípravu liečiv na neutralizáciu antitrombotickej aktivity syntetických polysacharidov
US8492352B2 (en) Polysaccharides with antithrombotic activity, including a covalent bond and an amino chain
US8703738B2 (en) Biotinylated hexadecasaccharides, preparation and use thereof
SK283411B6 (sk) Syntetické polysacharidy, spôsob ich prípravy, farmaceutické kompozície, ktoré ich obsahujú, a použitie
CZ299817B6 (cs) Nové pentasacharidy, zpusob jejich prípravy a farmaceutické kompozice, které je obsahují
JP2013537181A (ja) 抗血栓活性及び改善された代謝安定性を有するビオチン化多糖類

Legal Events

Date Code Title Description
MM4A Patent lapsed due to non-payment of maintenance fees

Effective date: 20120920

MM4A Patent lapsed due to non-payment of maintenance fees

Effective date: 20160920